Erika Vanessa Oliveira Jorge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Erika Vanessa Oliveira Jorge has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Patricia Jeanne de Souza Mendonça Mattos
Laboratory of Immunogenetics, Foundation Center of Hemotherapy and Hematology of Pará (HEMOPA Foundation), Belém, Pará, Brazil; Preceptors of the State Program of Incentives to Qualification of Health Professionals - QUALIFICASAÚDE, Pará State University (UEPA), Belém, Pará, Brazil
2 shared publications Ana Caroline Cunha Messias
Dermato‐Immunology Laboratory Federal University of Pará Marituba Pará Brazil
1 shared publicationAngélica Rita Gobbo
Dermato‐Immunology Laboratory Federal University of Pará Marituba Pará Brazil
1 shared publication- Brenda Pinto de Moraes
Universidade da Amazônia (UNAMA)
1 shared publication - Claudio Guedes Salgado
Laboratório de Dermato-Imunologia, Universidade Federal do Pará, Marituba, Pará, Brazil
1 shared publication Débora Cristina Ricardo Porchera
Fundação Centro de Hemoterapia e Hematologia do Pará
1 shared publication
Latest Publications
- Open Access
- 3 July 2025
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (9) , 1018-1022
Leprosy in blood donors
Objectives: We investigated the prevalence of anti‐phenolic glycolipid‐I (PGL‐I) IgM antibodies among temporarily unfit blood donors at the Pará State Blood Bank (HEMOPA), located in the Amazon region of northern Brazil. Using an arbitrary high cutoff for optical density (OD ≥0.750) in ELISA, a subset of donors was invited for clinical evaluation for leprosy.Methods: Temporarily unfit individuals were invited to participate, and blood samples were collected for anti‐PGL‐I IgM titration by ELISA. Donors with high OD values were referred for clinical examination, slit skin smear (SSS) bacilloscopy, and quantitative PCR (qPCR) targeting M. leprae‐specific repetitive element (RLEP) sequences from dermal scrapes of the earlobes and peripheral blood.Results: From an annual average of 2762 temporarily unfit donors (2019–2023), 500 (16.6%) were tested for anti‐PGL‐I IgM. Of these, 20/500 (4.0%) had high antibody titres, and 8/20 (40.0%) attended clinical evaluation, resulting in 5/8 (62.5%) newly diagnosed cases of leprosy. Among these, Mycobacterium leprae detection yielded positivity rates of 2/8 (25.0%) by SSS bacilloscopy, 3/7 (42.9%) by qPCR of dermal scrapes, and 2/8 (25.0%) by qPCR of peripheral blood.Conclusions: Using an anti‐PGL‐I IgM cutoff of OD ≥0.750, we identified a significant proportion of undiagnosed leprosy cases among temporarily unfit blood donors. These findings support the need for targeted leprosy screening in this population. Regardless of qPCR results, individuals with clinical signs of leprosy require appropriate treatment and assessment of their eligibility for blood donation.
- 3 July 2025
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (9) , 1018-1022
Open AccessLeprosy in blood donors
Objectives: We investigated the prevalence of anti‐phenolic glycolipid‐I (PGL‐I) IgM antibodies among temporarily unfit blood donors at the Pará State Blood Bank (HEMOPA), located in the Amazon region of northern Brazil. Using an arbitrary high cutoff for optical density (OD ≥0.750) in ELISA, a subset of donors was invited for clinical evaluation for leprosy.Methods: Temporarily unfit individuals were invited to participate, and blood samples were collected for anti‐PGL‐I IgM titration by ELISA. Donors with high OD values were referred for clinical examination, slit skin smear (SSS) bacilloscopy, and quantitative PCR (qPCR) targeting M. leprae‐specific repetitive element (RLEP) sequences from dermal scrapes of the earlobes and peripheral blood.Results: From an annual average of 2762 temporarily unfit donors (2019–2023), 500 (16.6%) were tested for anti‐PGL‐I IgM. Of these, 20/500 (4.0%) had high antibody titres, and 8/20 (40.0%) attended clinical evaluation, resulting in 5/8 (62.5%) newly diagnosed cases of leprosy. Among these, Mycobacterium leprae detection yielded positivity rates of 2/8 (25.0%) by SSS bacilloscopy, 3/7 (42.9%) by qPCR of dermal scrapes, and 2/8 (25.0%) by qPCR of peripheral blood.Conclusions: Using an anti‐PGL‐I IgM cutoff of OD ≥0.750, we identified a significant proportion of undiagnosed leprosy cases among temporarily unfit blood donors. These findings support the need for targeted leprosy screening in this population. Regardless of qPCR results, individuals with clinical signs of leprosy require appropriate treatment and assessment of their eligibility for blood donation.
- Open Access
- 1 March 2024
- Published by Editora RECIMA21 LTDA in RECIMA21 - Revista Científica Multidisciplinar
- Vol. 5 (3) , e534891
ANTÍGENO LEUCOCITÁRIO HUMANO DE CLASSE III: REVISÃO INTEGRATIVA
O Antígeno Leucocitário Humano de Classe III (HLA de Classe III) detém polimorfismos genéticos que se correlacionam com a etiopatogênese, suscetibilidade e gravidade de doenças que afetam os seres humanos. Objetivo: o estudo visa esclarecer o papel dos polimorfismos e as ações presentes do HLA de Classe III na sintomatologia e na patogênese de doenças crônicas, autoimunes, inflamatórias, carcinogênicas e infecciosas que afetam a humanidade. Metodologia: Trata-se de uma Revisão Integrativa, com base no acrônimo PCC e incluindo as bases de dados Biblioteca Virtual de Saúde (BVS), Capes Periódicos, Google Scholar, Embase, Medical Literature Analysis and Retrieval System Online (MEDLINE), Bibliografia Brasileira de Odontologia (BBO), ScienceDirect e Scopus. Utilizou-se como descritores termos de interesse encontrados no Medical Subject Headings (MeSH) e no Descritores das Ciências da Saúde (DeCS). Resultados: foram recuperados 56 estudos, sendo que 35 artigos de caso-controle, 3 artigos de estudo in vivo, 2 artigos de revisão de literatura, 15 artigos de estudo de coorte e 1 artigo de relato de caso. Os polimorfismos do HLA de Classe III devem-se a mutações isoladas e coordenadas com outros locus gênicos. Conclusão: os polimorfismos do HLA de Classe III podem corroborar diretamente ou indiretamente para doenças que afetam algumas populações humanas.
- 1 March 2024
- Published by Editora RECIMA21 LTDA in RECIMA21 - Revista Científica Multidisciplinar
- Vol. 5 (3) , e534891
Open AccessANTÍGENO LEUCOCITÁRIO HUMANO DE CLASSE III: REVISÃO INTEGRATIVA
O Antígeno Leucocitário Humano de Classe III (HLA de Classe III) detém polimorfismos genéticos que se correlacionam com a etiopatogênese, suscetibilidade e gravidade de doenças que afetam os seres humanos. Objetivo: o estudo visa esclarecer o papel dos polimorfismos e as ações presentes do HLA de Classe III na sintomatologia e na patogênese de doenças crônicas, autoimunes, inflamatórias, carcinogênicas e infecciosas que afetam a humanidade. Metodologia: Trata-se de uma Revisão Integrativa, com base no acrônimo PCC e incluindo as bases de dados Biblioteca Virtual de Saúde (BVS), Capes Periódicos, Google Scholar, Embase, Medical Literature Analysis and Retrieval System Online (MEDLINE), Bibliografia Brasileira de Odontologia (BBO), ScienceDirect e Scopus. Utilizou-se como descritores termos de interesse encontrados no Medical Subject Headings (MeSH) e no Descritores das Ciências da Saúde (DeCS). Resultados: foram recuperados 56 estudos, sendo que 35 artigos de caso-controle, 3 artigos de estudo in vivo, 2 artigos de revisão de literatura, 15 artigos de estudo de coorte e 1 artigo de relato de caso. Os polimorfismos do HLA de Classe III devem-se a mutações isoladas e coordenadas com outros locus gênicos. Conclusão: os polimorfismos do HLA de Classe III podem corroborar diretamente ou indiretamente para doenças que afetam algumas populações humanas.
- Open Access
- 1 January 2021
- Published by Brazilian Journal of Development in Brazilian Journal of Development
- Vol. 7 (2) , 18826-18843
AVALIAÇÃO DA FREQUÊNCIA ALÉLICA E HAPLOTÍPICA DO SISTEMA HLA PARA OS LOCI HLA-A, HLA-B E HLA-DRB1 DE RECEPTORES RENAIS E DOADORES INTERVIVO DO ESTADO DO PARÁ, BRASIL/ EVALUATION OF THE ALLELIC AND HAPLOTYPIC FREQUENCY OF THE HLA SYSTEM FOR HLA-A, HLA-B E HLA-DRB1 LOCI OF RENAL RECEPTORS AND LIVING DONORS FROM THE STATE OF PARÁ, BRAZIL
Avaliação da frequência alélica e haplotípica do sistema HLA para os loci HLA-A, HLA-B e HLA-DRB1 de receptores renais e doadores intervivo do estado do Pará, Brasil/ Evaluation of the allelic and haplotypic frequency of the HLA system for HLA-A, HLA-B e HLA-DRB1 loci of renal receptors and living donors from the state of Pará, Brazil
- 1 January 2021
- Published by Brazilian Journal of Development in Brazilian Journal of Development
- Vol. 7 (2) , 18826-18843
Open AccessAVALIAÇÃO DA FREQUÊNCIA ALÉLICA E HAPLOTÍPICA DO SISTEMA HLA PARA OS LOCI HLA-A, HLA-B E HLA-DRB1 DE RECEPTORES RENAIS E DOADORES INTERVIVO DO ESTADO DO PARÁ, BRASIL/ EVALUATION OF THE ALLELIC AND HAPLOTYPIC FREQUENCY OF THE HLA SYSTEM FOR HLA-A, HLA-B E HLA-DRB1 LOCI OF RENAL RECEPTORS AND LIVING DONORS FROM THE STATE OF PARÁ, BRAZIL
Avaliação da frequência alélica e haplotípica do sistema HLA para os loci HLA-A, HLA-B e HLA-DRB1 de receptores renais e doadores intervivo do estado do Pará, Brasil/ Evaluation of the allelic and haplotypic frequency of the HLA system for HLA-A, HLA-B e HLA-DRB1 loci of renal receptors and living donors from the state of Pará, Brazil